Active Filter(s):
Details:
The acquisition will facilitate DSM to anticipate in the rapidly extension of the availability of Lacteol (lactobacillus LB), an effective postbiotic treatment for diarrhea, engineered using adare's innovative microbiome technology platform, for people through its B2C unit.
Lead Product(s): Lactobacillus LB
Therapeutic Area: Gastroenterology Product Name: Lacteol
Highest Development Status: Approved Product Type: Large molecule
Recipient: Adare Biome
Deal Size: $302.8 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 19, 2023
Details:
Included in the acquisition are patents, trademarks, trade secret manufacturing processes, analytical methods, regulatory filings, and a large number of nonclinical and clinical safety studies.
Lead Product(s): Genistein
Therapeutic Area: Oncology Product Name: BIO 300
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Humanetics Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 19, 2020